Contact Us
Drug Search Results
More Filters [+]

Revusiran

Alternative Names: revusiran
Latest Update: 2021-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TTR Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alnylam
Company Location: CAMBRIDGE MA 02142
Company CEO: Yvonne L. Greenstreet
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Revusiran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Transthyretin Amyloidosis|Amyloidosis, Familial|Cardiomyopathies|Amyloid Neuropathies, Familial

Phase 2: Amyloidosis|Amyloidosis, Familial|Transthyretin Amyloidosis|Polyneuropathies|Amyloid Neuropathies, Familial

Phase 1: Amyloidosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2014-003835-20

P3

Completed

Transthyretin Amyloidosis

2017-03-30

ENDEAVOUR

P3

Completed

Transthyretin Amyloidosis|Cardiomyopathies|Amyloid Neuropathies, Familial|Amyloidosis, Familial

2017-03-30

2014-001229-34

P2

Completed

Transthyretin Amyloidosis

2017-02-22

ALN-TTRSC-003

P2

Completed

Amyloidosis

2017-02-22

Recent News Events

Date

Type

Title

01/01/2021

PubMed

 Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a 'treatabolome'.

12/01/2020

PubMed

 Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions